Dark

Check out our Level2View

EPZM
Epizyme, Inc
stock NASDAQ

Inactive

Aug 11, 2022

1.47USD-1.342%(-0.02)22,276,017

Pre-market

0.00USD-100.000%(-1.49)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 27, 2022

02:33PM EST Mid-Afternoon Market Update: US Stocks Turns Lower In Volatile Trading; Nasdaq Tumbles 150 Points Benzinga

12:12PM EST Mid-Day Market Update: Dow Jumps Over 500 Points; Seagate Shares Surge On Upbeat Results Benzinga

02:59AM EST Epizyme, Inc. (EPZM), a company focused on delivering novel epigenetic therapies, on Thursday announced the pricing of public offering of its 56.66 million shares at $1.50 per share. RTTNews

02:25AM EST Epizyme Announces Pricing Of Underwritten Public Offering Of 56.67 Mln Shares At $1.50/shr RTTNews

02:12AM EST Epizyme Announces Pricing of Public Offering of Common Stock Business Wire

Jan 26, 2022

04:20PM EST Epizyme Announces Proposed Public Offering Of Common Stock; No Terms Disclosed Benzinga

04:01PM EST Epizyme Announces Proposed Public Offering of Common Stock Business Wire

Jan 19, 2022

11:49AM EST Epizyme Granted FDA Orphan Designation For Treatment Of Multiple Myeloma Benzinga

Jan 10, 2022

07:35AM EST Epizyme Sees Q4 Preliminary TAZVERIK Net Product Revenue $11.2M-11.7M And FY21 TAZVERIK Net Product Revenue Of $30.6M-31.1M Benzinga

07:00AM EST Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates Business Wire

Jan 5, 2022

11:07AM EST Stocks That Hit 52-Week Lows On Wednesday Benzinga

Dec 22, 2021

04:13PM EST Epizyme 8-K Shows Co. Received Written Notice From Glaxo Group GSK Elected To Terminate Collab, License Deal With Epizyme Benzinga

Dec 21, 2021

06:40AM EST Epizyme Granted U.S. Patent #11,202,781 'EZH2 inhibitors for treating lymphoma' Benzinga

Dec 12, 2021

09:06AM EST Epizyme Presents Updates From SYMPHONY-1 Tazemetostat + R2 Study In Relapsed/Refractory Follicular Lymphoma At ASH RTTNews

09:00AM EST Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting Business Wire

Dec 11, 2021

10:26AM EST Epizyme Inc. (EPZM) said that data presented from both in vitro and in vivo preclinical studies, demonstrated that targeting SETD2 with EZM0414 resulted in significantly reduced growth of t(4;14) multiple myeloma cell lines, as well as non-t(4;14) multiple myeloma and diffuse large B-cell lymphoma cell lines. RTTNews

09:19AM EST Epizyme Presented Preclinical Data and Phase 1/1b Trial Design on the Company's SETD2 Inhibitor, EZM0414, at ASH 2021; CSO Said Data Highlights Anti-tumor Activity in Multiple Myeloma and DLBCL Xenograft Models Benzinga

09:00AM EST Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company's SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting Business Wire

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 2, 2021

06:30AM EST Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting Business Wire

Nov 30, 2021

04:49PM EST Epizyme Granted U.S. Patent #11,185,531 'Arginine methyltransferase inhibitors and uses thereof' Benzinga

Nov 18, 2021

06:30AM EST Epizyme Announces Updates to Its Board of Directors Business Wire

Nov 12, 2021

08:00AM EST Epizyme to Participate in Jefferies London Healthcare Conference Business Wire

Nov 10, 2021

11:50AM EST Epizyme's Return On Capital Employed Insights Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:28AM EST Epizyme Q3 EPS $(0.64) Misses $(0.48) Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

06:37AM EST Epizyme Q3 Net Loss $65.8 Mln Or $0.64/shr Vs. Net Loss $56.1 Mln Or $0.55/shr Last Year RTTNews

06:30AM EST Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update Business Wire

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 5, 2021

07:00AM EDT Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

06:42AM EDT Epizyme Reports Received Fast Track Designation From FDA, Initiated Phase 1/1b Study Of Novel SET Domain Containing 2 Inhibitor, EZM0414 Benzinga

06:39AM EDT Epizyme Gets Fast Track Designation From FDA; Initiates Phase 1/1b Study Of SETD2 Inhibitor, EZM0414 RTTNews

06:30AM EDT Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 Business Wire

Nov 2, 2021

06:30AM EDT Epizyme Announces Date of Third Quarter 2021 Financial Results Business Wire

Nov 1, 2021

08:00AM EDT Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making Business Wire

Oct 19, 2021

10:11AM EDT Epizyme Granted U.S. Patent Titled 'EZH2 inhibitors for treating cancer' Benzinga

Oct 7, 2021

07:08AM EDT Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

Sep 14, 2021

06:35AM EDT Epizyme Presents Data From TAZVERIK Clinical Programs At 2021 ESMO Congress RTTNews

06:33AM EDT Epizyme Announces Data From TAZVERIK Clinical Programs To Be Presented During Poster Sessions At 2021 ESMO Virtual Congress Sept. 16-21 Benzinga

06:30AM EDT Epizyme Announces Data from TAZVERIK(r) (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress Business Wire

Aug 20, 2021

08:06AM EDT Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

08:08AM EDT Morgan Stanley Downgrades Epizyme to Underweight, Lowers Price Target to $5 Benzinga

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

06:32AM EDT HC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $15 Benzinga

Aug 9, 2021

03:50PM EDT Epizyme Shares Volatile As Hearing Morgan Stanley Downgrades Stock To Underweight Benzinga

12:18PM EDT Epizyme Late Sunday Announced Strategic Collaboration With HUTCHMED To Develop, Commercialize TAZVERIK In Greater China; Co. Received Upfront $25M Payment, Up To $285M In Potential Milestones Benzinga

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

07:53AM EDT Recap: Epizyme Q2 Earnings Benzinga

07:44AM EDT Epizyme CEO Robert Bazemore To Step Down, Grant Bogle Named Incoming CEO Benzinga

07:39AM EDT Epizyme Q2 EPS $(0.63) Misses $(0.62) Estimate, Sales $13.00M Beat $8.72M Estimate Benzinga

07:39AM EDT Epizyme Says Grant Bogle Succeeding Robert Bazemore, As President And CEO RTTNews

07:37AM EDT Epizyme Q2 Total Revenue Rises To $13.0 Mln From $2.5 Mln Last Year RTTNews

07:35AM EDT Epizyme Announces CEO Succession Business Wire

07:30AM EDT Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update Business Wire

06:15AM EDT Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

09:34PM EDT Epizyme Inc. (EPZM) and Hutchmed (China) Limited said that they have collaborated to research, develop, manufacture and commercialize Tazverik or tazemetostat in Greater China, including mainland China, Hong Kong, Macau and Taiwan. RTTNews

08:59PM EDT Epizyme And HUTCHMED Collaborats To Develop & Commercialize TAZVERIK In Greater China RTTNews

08:00PM EDT Collaboration designed to accelerate global development and investigate TAZVERIK combinations with HUTCHMEDs novel oncology medicines portfolio GlobeNewswire Inc

08:00PM EDT Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK(r) (tazemetostat) in Greater China Business Wire

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 3, 2021

04:02PM EDT Epizyme Announces Date of Second Quarter 2021 Financial Results Business Wire

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jun 28, 2021

05:25PM EDT Epizyme 8-K Shows Co. CFO, Paolo Tombesi, Toi Leave Co.; VP, Chief Strategy, Business Officer, Matthew Ros, To Serve As Principal Financial Officer Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

06:35AM EDT Epizyme Launches EZH2Now Testing Program With Quest Diagnostics For Relapsed Or Refractory Follicular Lymphoma Patients RTTNews

Jun 14, 2021

12:59PM EDT Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models Benzinga

May 27, 2021

09:55AM EDT Epizyme Files For U.S. Patent Application Titled 'CARM1 INHIBITORS AND USES THEREOF' Benzinga

May 25, 2021

06:30AM EDT Epizyme to Participate in Jefferies Virtual Healthcare Conference Business Wire

May 12, 2021

04:09PM EDT Epizyme Announces Preclinical And Clinical Data To Be Presented In Oral And Poster Sessions At The Upcoming Medical Conferences in June Benzinga

May 7, 2021

03:03PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop Benzinga

12:20PM EDT Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021 Benzinga

08:06AM EDT Morgan Stanley Maintains Equal-Weight on Epizyme, Lowers Price Target to $10 Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

06:51AM EDT SVB Leerink Upgrades Epizyme to Outperform, Raises Price Target to $16 Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

06:53AM EDT Epizyme Q1 EPS $(0.69) Misses $(0.58) Estimate, Sales $7.60M Beat $6.56M Estimate Benzinga

06:30AM EDT Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results Business Wire

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

06:30AM EDT Epizyme Announces Date of First Quarter 2021 Financial Results Business Wire

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 20, 2021

10:31AM EDT Epizyme Granted U.S. Patent Titled 'PRMT5 inhibitors and uses thereof' Benzinga

Apr 19, 2021

10:32AM EDT Morgan Stanley Maintains Equal-Weight on Epizyme, Lowers Price Target to $11 Benzinga

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:12AM EDT Credit Suisse Initiates Coverage On Epizyme with Outperform Rating, Announces Price Target of $13 Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 16, 2021

05:37AM EDT Epizyme Awarded U.S. Patent 10,946,024 'Method for treating cancer' Benzinga

Mar 11, 2021

08:19AM EST The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena Benzinga

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 2, 2021

12:01PM EST Epizyme Outlines Co.'s Strategic Vision, Focus On Oncology Treatment For Co.'s Epigentic Pipeline Benzinga

12:00PM EST Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company's Strategic Vision Call Business Wire

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2021 Benzinga

07:06AM EST Morgan Stanley Downgrades Epizyme to Equal-Weight, Announces $14 Price Target Benzinga

Feb 24, 2021

06:30AM EST Epizyme to Host Strategic Vision Call on March 2, 2021 Business Wire

Feb 23, 2021

10:31AM EST CORRECTING and REPLACING Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

10:04AM EST Return On Capital Employed Overview: Epizyme Benzinga

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

07:24AM EST Epizyme: Q4 Earnings Insights Benzinga

06:38AM EST Epizyme Q4 Total Revenue Rises To $8.4 Mln, From $4.3 Mln Last Year RTTNews

06:32AM EST Epizyme Q4 EPS $(0.65) Misses $(0.58) Estimate, Sales $8.40M Beat $6.19M Estimate Benzinga

06:30AM EST Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 16, 2021

06:30AM EST Epizyme Announces Date of Fourth Quarter and Full Year 2020 Financial Results and Participation in Upcoming Investor Conferences Business Wire

Jan 25, 2021

12:33PM EST Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation Benzinga

Dec 21, 2020

10:07AM EST Benzinga's Top Upgrades, Downgrades For December 21, 2020 Benzinga

08:07AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:39AM EST Jefferies Downgrades Epizyme to Hold, Lowers Price Target to $14 Benzinga

Nov 13, 2020

12:56PM EST Insider Buys Epizyme's Shares Benzinga

Nov 11, 2020

04:05PM EST Epizyme to Participate in Jefferies Virtual London Healthcare Conference Business Wire

Nov 9, 2020

08:19AM EST Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $27 Benzinga

Nov 6, 2020

02:45PM EST Stocks Trading Near 52-Week Lows On Friday, Nov. 6, 2020: ASRT, KBLMU, PNRG, YGMZ, APRE, UHT, LAIX, CLI, CORR, ANIP, CCOI, KBLM, NYC, UTL, PEI, TIG, EYEG, PVL, ZSAN, TTNP, NBRV, SFT, WPG, IFS, COGT, LMNL, PRFX, GBT, FNHC, ASMB, EPZM, UCL Benzinga

10:25AM EST Shares of drug maker Epizyme, Inc. (EPZM) are falling more than 18% Friday morning at $11.02 after the company reported wider loss for the third quarter. RTTNews

07:53AM EST Recap: Epizyme Q3 Earnings Benzinga

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

06:41AM EST Epizyme Names Karen Lynch Next President And CEO; Larry Merlo To Retire In Spring 2021 RTTNews

06:35AM EST Epizyme Cuts FY20 Adj. Cash Operating Expenses Guidance From $235M-$255M To $215M-$235M Benzinga

06:35AM EST Epizyme Q3 EPS $(0.55) Beats $(0.60) Estimate, Sales $3.60M Miss $5.43M Estimate Benzinga

06:32AM EST Epizyme Reports Business Progress and Third Quarter 2020 Financial Results Business Wire

06:20AM EST Epizyme Reports Expansion Of Loan Facility With Pharmakon Advisors For Added $150M To Fund Growth Initiatives Benzinga

06:05AM EST Epizyme Announces Expanded Loan Facility with Pharmakon Advisors for Additional $150 Million to Fund its Growth Initiatives Business Wire

03:33AM EST Earnings Scheduled For November 6, 2020 Benzinga

Nov 3, 2020

08:07AM EST Epizyme, Inc. Granted Patent by USPTO Number 10,821,113 Dated November 3, 2020 Titled 'Salt form of a human histone methyltransferase EZH2 inhibitor' Benzinga

Oct 30, 2020

06:30AM EDT Epizyme Announces Date of Third Quarter 2020 Financial Results Business Wire

Oct 7, 2020

06:41AM EDT Epizyme Says TheLancet Oncology Published Results Of Phase 2 Trial Cohorts Evaluating TAZVERIK RTTNews

06:33AM EDT Epizyme Highlights Two Lancet Oncology Publications On TAZVERIK Phase 2 Data In Epithelioid Sarcoma And Follicular Lymphoma Benzinga

06:30AM EDT Epizyme Announces Two Lancet Oncology Publications on TAZVERIK(r) (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma Business Wire

Sep 8, 2020

06:30AM EDT Epizyme to Participate in Morgan Stanley 18th Annual Global Healthcare Conference Business Wire

Aug 5, 2020

10:14AM EDT Morgan Stanley Maintains Overweight on Epizyme, Lowers Price Target to $29 Benzinga

Aug 4, 2020

07:18AM EDT Recap: Epizyme Q2 Earnings Benzinga

06:41AM EDT Epizyme Q2 EPS $(0.58) Beats $(0.61) Estimate, Sales $2.47M Miss $4.30M Estimate Benzinga

06:38AM EDT Epizyme Posts Q2 Net Loss Of $58.5 Mln Or $0.58/shr RTTNews

06:30AM EDT Epizyme Reports Business Progress and Second Quarter 2020 Financial Results Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 28, 2020

06:30AM EDT Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire

Share